News
DGAP-News: 4SC AG: Poster presentation at 1st International Symposium on Merkel Cell Carcinoma
DGAP-Adhoc: Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders
DGAP-Adhoc: Epigenomics AG beschließt Kapitalerhöhung mit Bezugsrecht der Aktionäre
DGAP-News: 4SC provides Q3 business update and outlook
DGAP-News: 4SC berichtet über Geschäftsentwicklung im dritten Quartal und veröffentlicht Ausblick
DGAP-News: 4SC und das Netherlands Cancer Institute kooperieren bei der klinischen Evaluierung von Domatinostat zur neoadjuvanten Therapie des Melanoms
DGAP-News: 4SC and Netherlands Cancer Institute Collaborate on Clinical Evaluation of Domatinostat in the Neoadjuvant Setting in Melanoma
DGAP-Adhoc: Biofrontera AG: Biofrontera reports preliminary unaudited sales revenue for the first nine months of 2019
DGAP-Adhoc: Biofrontera AG: Biofrontera gibt vorläufige ungeprüfte Umsatzerlöse für die ersten neun Monate des Geschäftsjahrs 2019 bekannt
DGAP-News: 4SC AG: Telefonkonferenz am 17. Oktober 2019 zur Quartalsmitteilung Q3 2019
DGAP-News: 4SC AG: Conference call to be hosted on 17 October 2019 to present the Q3 Announcement 2019
DGAP-News: MOLOGEN AG: Cooperation with amfAR Institute for HIV Cure Research on clinical combination trial
DGAP-News: MOLOGEN AG: Kooperation mit amfAR Institute for HIV Cure Research für klinische Kombinationsstudie
DGAP-Adhoc: 4SC AG beschließt Ausgabe neuer Aktien; Santo und ATS verpflichten sich zur Zeichnung bzw. zum Kauf der neuen Aktien
DGAP-Adhoc: 4SC AG resolves to issue new shares; Santo and ATS undertake to subscribe / buy the new shares
Could This Be the Catalyst Novavax Needs to Get Its Stock Rallying Again?
Struggling biotech Novavax (NASDAQ: NVAX) was a hot buy a few years ago as it was in the midst of developing a vaccine for COVID-19. Ultimately, it did produce an approved vaccine, but it was a bit
EQS-News: Biotest AG opens 13th plasma collection center in Germany
The Best Biotech Stock to Invest $1,000 in Right Now
In biotech, sometimes it's the companies that aren't making a single dime that end up being the very best investments after a short time. For instance, Viking Therapeutics (NASDAQ: VKTX) doesn't yet
3 Billionaire-Held Stocks to Buy Now
When looking at the top bets of some of the most prominent billionaire investors, there is a common theme that stands out. These professionals are favoring highly profitable companies that dominate
EQS-News: Dr. Jörg Schüttrumpf resigns from the Management Board of Biotest AG
Why Viking Therapeutics Stock Got Thrashed on Tuesday
News from a deep-pocketed rival put the hurt on biotech Viking Therapeutics's (NASDAQ: VKTX) stock on Tuesday. Said rival seems determined to dominate a very hot therapeutic area these days, and it
Could This Under-the-Radar Company Be the Best Cruise Line Stock?
When most people think of the cruise industry, companies like Royal Caribbean (NYSE: RCL) and Carnival Cruise Lines (NYSE: CCL) come to mind. However, unique cruise operator Viking River Cruises
Prediction: This Hypergrowth Space Stock Will Be Worth More Than SpaceX In 10 Years
SpaceX has been a remarkable success over the last 15 years. It brought the space flight industry in the United States -- really, around the world -- back to life and inspired plenty of copycats
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Exciting trends are sweeping through the biotech industry. One of them is the race to develop breakthrough weight loss medicines, an area that is projected to grow by leaps and bounds through the
Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now?
Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage drugmaker working on metabolic treatments, have tripled in value this year. Despite the huge run-up, analysts who follow the company